Rhythm Pharmaceuticals, Inc. (RYTM) News
Follow Rhythm Pharmaceuticals, Inc. (RYTM) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 17 public stories across 11 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm
NEW YORK, Sept. 28, 2026 // -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) breached their fiduciary duties to
NEWS | Sep 28, 2026, 01:10 PM UTC
M
Health Canada approves Rhythm’s IMCIVREE for weight management
RYTM - Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity
REGULATION | Sep 22, 2026, 12:04 PM UTC
L
Rhythm Pharmaceuticals Coverage Assumed by Leerink Partners at Outperform
Ratings actions from Benzinga: GMT) Rhythm Pharmaceuticals Price Target Announced at $133.00/Share by Leerink PartnersRatings actions from Benzinga
NEWS | Sep 14, 2026, 09:09 PM UTC
L
Rhythm Pharmaceuticals presents real-world setmelanotide BMI and risk results
Real-world data showed reductions in BMI with up to 18 months of setmelanotide therapy in 30 paediatric patients with acquired hypothalamic obesity (HO) in France. Phase 3 analyses demonstrated improvements across multip
EQUITY | Sep 10, 2026, 12:04 PM UTC
L
RYTM - Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting - Click For Rele
RYTM - Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting
EQUITY | Sep 10, 2026, 12:00 PM UTC
L
RYTM: HO launch gains traction, Prader-Willi trials advance, and financials support robust investment
The business is advancing three rare disease pillars, with a strong HO launch showing broad prescriber engagement and favorable payer trends. Prader-Willi development is progressing with positive phase II data and strate
EQUITY | Sep 09, 2026, 08:51 PM UTC
L
RYTM early HO launch momentum and Prader-Willi plans drive growth
The conference cited strong early momentum in the HO launch, broad prescriber engagement and favorable payer dynamics. It also highlighted Prader-Willi syndrome as a major strategic focus, with robust Phase II data and p
MACRO | Sep 09, 2026, 08:13 PM UTC
L
Deutsche Bank initiates Rhythm Pharmaceuticals at Hold
Deutsche Bank initiated coverage of Rhythm Pharmaceuticals with a Hold rating.
EQUITY | Aug 28, 2026, 01:09 PM UTC
L
RYTM - Imcivree Approval In Japan Represents Meaningful Growth opportunity @ MSCO
RYTM - Imcivree Approval In Japan Represents Meaningful Growth opportunity @ MSCO
EQUITY | Aug 24, 2026, 12:56 PM UTC
M
Rhythm Pharmaceuticals wins Japan approval for IMCIVREE in acquired hypothalamic obesity
Rhythm Pharmaceuticals says Japan’s MHLW approved IMCIVREE (setmelanotide) for patients with acquired hypothalamic obesity in Japan.
REGULATION | Aug 24, 2026, 12:01 PM UTC
M
Rhythm wins Japan approval for Imcivree in acquired HO
Rhythm Pharmaceuticals says Japan's MHLW approves Imcivree (setmelanotide) for patients with acquired hypothalamic obesity, with launch in Japan expected by end of 2026 pending pricing.
EQUITY | Aug 24, 2026, 12:00 PM UTC
L
Rhythm Pharmaceuticals appoints Manher (AJ) Joshi as CMO
Rhythm Pharmaceuticals (RYTM) announces the appointment of Manher (AJ) Joshi as Chief Medical Officer.
EQUITY | Aug 17, 2026, 12:01 PM UTC
L
RYTM - Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update
RYTM - Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update
EARNINGS | Aug 04, 2026, 01:33 PM UTC
H
Rhythm Pharmaceuticals Reports Positive Efficacy Signal
Rhythm Pharmaceuticals shows positive efficacy in phase 2 trial
EQUITY | Aug 04, 2026, 10:55 AM UTC
L
RYTM Initiated Overweight W/$145.00 PT at JPMorgan
RYTM Initiated Overweight W/$145.00 PT at JPMorgan
EQUITY | Jul 27, 2026, 12:08 PM UTC
L
Top Initiations: BSP DFTX GHRS HELP MDGL: OVERWEIGHT @ WFC CMPS: EQUAL WEIGHT @ WFC CIFR HIVE PMN WULF: BUY @ Chardan BWXT CDRE LIME RYTM: O
Top Initiations: BSP DFTX GHRS HELP MDGL: OVERWEIGHT @ WFC CMPS: EQUAL WEIGHT @ WFC CIFR HIVE PMN WULF: BUY @ Chardan BWXT CDRE LIME RYTM: OVERWEIGHT @ JPM CLH ITG: BUY @ BAC ARLO WSM: OVERWEIGHT @ Piper ADUR: BUY @ ROTH
EQUITY | Jul 27, 2026, 11:09 AM UTC
L
RYTM Reiterate Market Outperform, $155 PT following HO survey for Imcivree @ Citizens
RYTM Reiterate Market Outperform, $155 PT following HO survey for Imcivree @ Citizens
EQUITY | Jul 14, 2026, 11:37 AM UTC